애보트(ABT) 2026년 3분기 실적 발표 콘퍼런스 콜: 뉴트리션 부문 분사 및 매출 7% 성장

핵심 요약

• 애보트(NYSE: ABT)는 2026년 3분기 비교 매출이 7% 증가했다고 발표했다. 같은 기간 주당순이익(EPS)은 9% 늘었으며, 조정 EPS는 1.42달러를 기록했다.
• 애보트는 필요한 승인 절차를 거쳐 2027년 말까지 영양(Nutrition) 사업부를 독립 상장기업으로 분사할 계획이다. 해당 사업부는 연간 약 85억 달러의 매출을 올리고 있으며, 직원 수는 1만 6000명에 달한다.
• 애보트는 분사 이후 포트폴리오의 매출 성장률이 50~100bp 가속화되고, 총이익률은 200bp 이상, 영업이익률은 약 100bp 개선될 것으로 전망하고 있다.
• 의료기기 부문 매출은 전기생리학 및 부정맥 관리 부문의 두 자릿수 성장에 힘입어 8% 증가했다. 진단 부문은 암 진단의 14% 성장을 포함해 6.5% 증가했다.
• 경영진은 2026년 4분기 조정 EPS를 1.62~1.67달러로 예상하고 있다. 연간 비교 매출 성장률은 약 6%로 전망되며, 이는 4분기 성장률이 8%를 살짝 상회함을 의미한다.
• 단기적 압력은 좌심방이 관련 영향이 전극도자절제술(ablation) 성장을 상쇄하고 있는 전기생리학 부문과, 해외 가격 하락 압력 및 제한적인 보험 급여 확대로 성장이 둔화하고 있는 당뇨 관리 부문에 집중되어 있다.

주요 재무 데이터

사업 및 영업 실적

영양 사업부 분사 계획

애보트는 새로 독립하는 영양 부문 회사의 주식을 기존 주주들에게 배분할 계획이다. 거래가 완료되면 주주들은 애보트와 신설 법인 모두의 주식을 보유하게 된다. 최종 배분 비율은 거래 종료 전에 발표될 예정이다.

영양 사업부는 연간 약 85억 달러의 매출, 1만 6000명의 직원, 14개의 제조 시설을 보유하고 있다. 포트폴리오에는 씨밀락(Similac), 페디아슈어(PediaSure), 엔슈어(Ensure), 글루세르나(Glucerna), PDL 등이 포함된다. 다니엘 살바도르(Daniel Salvador)가 신설 회사의 최고경영자(CEO)로 취임할 예정이다.

경영진은 이번 분사가 영양 사업부와 애보트의 남은 헬스케어 사업 간의 고객층, 성장 프로필, 투자 요구사항 및 혁신 주기가 점차 차별화되고 있음을 반영한 것이라고 밝혔다. 신설 법인은 차입을 통해 자금을 조달할 것으로 예상되며 조달 금액 중 일부는 애보트에 배분될 예정이나, 구체적인 액수는 아직 정해지지 않았다.

애보트는 분사 시점 두 회사의 합산 배당금이 당시 애보트의 배당금 수준과 같을 것으로 예상한다. 분사 관련 비용은 특정 항목(specified items)으로 처리되어 조정 실적에서 제외된다.

진단 부문

진단 부문 매출은 6.5% 증가했다. 미국, 유럽, 일본, 라틴아메리카의 호조에 힘입어 진단검사의학(Core Laboratory) 매출은 5.5% 늘었다. 경영진은 분기 동안 검사 수요가 견조하고 안정적으로 유지되었다고 밝혔다.

암 진단 매출은 콜로가드(Cologuard)와 정밀 온콜로지(Precision Oncology) 및 해외 사업의 기여로 14% 성장했다. 애보트는 9월에 첫 혈액 기반 대장암 선별검사를 출시하여 기존 분변 기반 선별검사 포트폴리오를 확장했다.

경영진은 7월에 발생한 사이버 보안 사고로 일부 연계된 의료 시스템이 임시로 수동 프로세스로 전환되면서 암 진단 매출 성장률이 약 1%포인트 감소했다고 밝혔다. 영업 활동은 약 7~10일 후 회복되었다.

경영진에 따르면 인수한 암 진단 사업은 인수 전 소폭에 불과했던 영업이익률이 3분기 말 기준 10%대 후반으로 상승했다.

영양 부문

영양 부문 매출은 미국 및 글로벌 소아·성인 카테고리 전반의 성장에 힘입어 5% 증가했습니다.

소아 영양 부문은 미국 내 11% 성장을 포함해 9% 성장했습니다. 애보트는 미국 실적 호조의 원인 중 하나로 저소득층 영유아 영양지원 프로그램(WIC) 계약 수주를 꼽았습니다. 성인 영양 부문은 미국 내 3.5% 성장을 포함해 2% 증가했습니다.

전 세계 영양 부문 매출은 전분기 대비 1억 달러 이상 증가했습니다. 애보트는 또한 해당 분기 동안 전유로 만든 액상형 시밀락(Similac) 영유아 조제유를 출시했습니다.

기성 의약품 부문

기성 의약품 부문 매출은 8.5% 증가했습니다. 아시아, 라틴아메리카, 중동의 여러 시장에서 두 자릿수 증가율을 기록하는 등 지역과 치료 영역 전반에서 광범위한 성장이 나타났습니다.

경영진은 바이오의약품의 독점권 만료 예정과 신흥 시장에서 애보트가 보유한 규제 기관, 정부, 의료진 및 유통망과의 기존 관계를 근거로 들며 바이오시밀러를 장기적 기회요인으로 강조했습니다.

의료기기 부문

의료기기 부문 매출은 전기생리학 및 심장 리듬 관리 부문의 두 자릿수 성장에 힘입어 8% 증가했습니다.

전기생리학 부문 성장률은 10%대 중반을 기록했으며, 좌심방이(LAA) 카테고리를 제외하면 10%대 후반에 달했습니다. 미국 내 성장률은 10%대 후반이었으며 해당 카테고리를 제외하면 20%를 상회했습니다. 애보트는 이러한 실적의 원인으로 8월 중순 미국 시장에 본격 출시된 Volt PFA 카테터의 채택 확대를 꼽았습니다.

유럽 전기생리학 부문 매출은 25% 증가했습니다. 애보트는 2026년 4분기 중 일본에서 Volt를 출시하고, 4분기 중 FDA 승인을 받은 TactiFlex Duo 카테터의 미국 내 본격적인 출시에 나설 계획입니다.

심장 리듬 관리 부문 매출은 단일 챔버 및 이중 챔버 영역 전반에서 AVEIR 비전극선 인공심박동기 플랫폼의 채택이 확대됨에 따라 10% 증가했습니다.

연속혈당측정기(CGM) 매출은 8% 증가했습니다. 애보트는 2026년 12월 미국에서 글루코스-케톤 이중 바이오웨어러블 센서인 리브레 듀오(Libre Duo)를 출시할 예정입니다.

경영진 가이던스

경영진은 이제 연간 동일비교 매출 성장률이 약 6%에 달할 것으로 예상하고 있습니다. 이러한 전망은 4분기 성장률이 8%를 살짝 상회하며 3분기 대비 가속화될 것임을 의미합니다.

애보트는 4분기 조정 주당순이익(EPS)을 1.62달러에서 1.67달러로 전망하고 있습니다. 현재 환율 기준으로 환율 변동이 4분기 매출 성장률을 약 1%포인트 감소시킬 것으로 예상됩니다.

2027년의 경우 경영진은 초기 매출 성장 가정이 2026년과 유사할 것으로 보인다고 밝히면서, 공식 가이던스는 1월에 제공될 것임을 강조했습니다. 회사는 지속적인 EPS 성장과 매출총이익률 확대를 예상하고 있으나 구체적인 수치 범위를 제시하지는 않았습니다.

당뇨 관리 부문에서 경영진은 향후 몇 분기 동안 성장률이 이전의 한 자릿수 후반 전망에 비해 한 자릿수 초중반에 머물 것으로 예상하고 있습니다. 인슐린을 사용하지 않는 2형 당뇨 환자에 대한 잠재적 CGM 보험 급여 확대는 현재 회사의 계획 가정에 포함되어 있지 않습니다.

리스크 및 주의 깊게 살펴볼 부분

• 전기생리학 부문 역풍: 좌심방이 시장의 약세와 애보트의 Amulet 360 기기를 기다리는 고객들로 인해 견조한 절제술 성장세가 상쇄되고 있습니다. 경영진은 이러한 흐름이 4분기까지 이어질 것으로 예상합니다.
• CGM 가격 정책 및 보험 급여: 애보트는 추가적인 보험 급여 없는 2형 당뇨 환자군에 대한 더딘 침투율과 해외 시장에서의 예상보다 조기 발생한 가격 인하 압력을 원인으로 꼽았습니다.
• 환율 영향: 현재 환율 수준은 4분기 매출 성장률을 약 1% 감소시킬 것으로 예상됩니다.
• 사이버 보안: 7월에 발생한 사고로 인해 암 진단 관련 업무가 7일에서 10일간 차질을 빚었으며, 분기 성장률이 약 1%포인트 감소했습니다.
• 영양 부문 소송: 경영진은 소송 해결이 분사의 전제 조건은 아니라고 밝혔습니다. 회사는 관련 부채가 애보트와 신설 영양 법인 사이에 어떻게 배분될지 아직 구체적으로 밝히지 않았습니다.
• 실행 리스크: 영양 부문 분사는 필요한 승인 절차를 거쳐야 하며, 최종 자본 구조, 채권 발행 및 주주 배정 비율은 아직 결정되지 않았습니다.

애널리스트 Q&A 주요 내용

경영진은 매각이 상당한 세금 문제와 통제하기 어려운 일정을 야기할 수 있어 매각보다 인적분할(스핀오프)을 선호했다고 밝혔습니다. 애보트는 영양사업부가 독립 기업일 때 마케팅, 혁신 및 잠재적 보완적 인수합병(tuck-in)에 투자하기에 더 적합한 입지를 갖추게 된다고 판단하고 있습니다.

매출 전망치 하향 조정과 관련해 경영진은 전기생리학과 당뇨 관리 부문을 주요 원인으로 짚었습니다. 전기생리학 부문 성장률은 4분기에 약 20%를 기록할 것으로 예상되며, 이는 회사의 이전 예상치보다 약 5%포인트 낮은 수준이지만, 경영진에 따르면 여전히 시장 점유율을 확대하고 있습니다.

애보트는 심장 리듬 관리, 구조적 심장 질환, 혈관 관리, 당뇨 및 암 진단 전반에 걸쳐 광범위한 제품 파이프라인을 보유하고 있다고 설명했습니다. 2026년 R&D 지출은 코로나19 이전의 연간 약 17억~18억 달러와 비교해 30억 달러를 초과할 것으로 예상됩니다.

경영진은 영양 부문 분사가 애보트의 인수합병 여력을 제한하지 않는다고 말했습니다. 단기적인 인수합병은 대규모 구조재편성 인수보다는 보완적 거래(tuck-in)가 될 가능성이 높습니다. 애보트는 순부채 대비 EBITDA 비율을 약 2배 수준으로 예상하고 있으며, 배당, 자사주 매입 및 M&A에 대한 여력을 유지하고 있다고 밝혔습니다.

실적 발표 콘퍼런스 콜 전문

전체 실적 발표 컨퍼런스 콜 녹취록

경영진 발표

Operator

Good morning and thank you for standing by. Welcome to Abbott's Third Quarter 2026 Earnings Conference Call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any participant's questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission.

I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations.

Michael Comilla

Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; and Phil Boudreau, Executive Vice President, Finance and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions.

Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Form 10-K for the year ended December 31, 2025.

Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com.

Note that Abbott has not provided the related GAAP financial measures on a forward-looking basis for the non-GAAP financial measures for which it is providing guidance because the company is unable to predict with reasonable certainty and without unreasonable effort, the timing and impact of certain items, which could significantly impact Abbott's results in accordance with GAAP. Unless otherwise noted, our commentary on sales growth refers to comparable sales growth. Our definition of comparable sales growth can be found on Page 2 of our press release issued earlier today. and a reconciliation table containing the data needed to calculate comparable sales growth can be found on Pages 16 and 17.

With that, I will now turn the call over to Robert.

Robert Ford

Thanks, Mike. Today marks an important milestone in Abbott's history, along with reporting our third quarter results, we announced our intention to separate our Nutrition business into an independent publicly traded company. This decision follows a comprehensive strategic review and reflects our strong belief that both Abbott and the Nutrition business can create greater value and achieve their maximum potential as independent organizations. Abbott entered the Nutrition business more than 60 years ago. Since that time, we built a strong foundation anchored by a talented global organization, iconic brands, and established market leadership positions across the pediatric and adult nutrition categories.

The nutrition market has evolved over time with the pace of change accelerating significantly in recent years. What was once predominantly viewed as a health care market, almost excludably shaped by health care professionals, has increasingly become in market shape by changing consumer preferences, wellness trends and retail execution. While this market evolution is not inherently positive or negative, it has fundamentally changed the environment in which we operate. So to best position our Nutrition business for maximum long-term success, we must evolve and adapt accordingly. At the same time, Abbott has strategically repositioned its portfolio over the past decade into attractive, high-growth markets that require sustained investment to drive innovation and support long-term growth.

So we believe both businesses will be better positioned for the future as independent organizations, each with a distinct identity reflecting their different customer bases, growth profiles, investment requirements and innovation cycles. In this separation will enable both companies to sharpen strategic and operational focus, direct resources more effectively and enhanced commercial and R&D effectiveness. As an independent company, Nutrition will be uniquely positioned to capitalize on the growing demand for healthy nutrition as consumers increasingly recognize the importance of metabolic health and the role of healthy nutrition plays in disease prevention and overall illness. The new nutrition company will be created from a position of strength. The team has done an exceptional job building a balanced growth model, supported by sustainable mix of volume and price.

The portfolio includes several iconic brands, including Similac, PediaSure, Ensure, Glucerna and PDL, which have market-leading positions across the pediatric and adult nutrition categories. With approximately $8.5 billion in annual sales, 16,000 employees and 14 manufacturing sites, this will be the largest globally scaled pure-play company in the healthy nutrition market. Given its scale and financial profile, we would expect this new company to qualify for inclusion in the S&P 500. I'm pleased to share that Daniel Salvador, Executive Vice President and Group President of Established Pharmaceuticals and Nutrition Products will become Chief Executive Officer of the new nutrition company. Daniel joined Abbott in 2014 as Senior Vice President in our Established Pharmaceuticals business for Latin America and also served as Executive Vice President of Nutrition Products for 4 years before being appointed to its current position in 2021. Throughout his career at Abbott, Daniel has demonstrated outstanding strategic insight and operational excellence. His broad international experience and proven track record of delivering results as a business operator, make him exceptionally well suited for this role, and I'm confident he will be a tremendous success. Daniel will be joined by an experienced leadership team with deep industry experience. And this is a battle-tested team that has demonstrated exceptional resilience and dedication while navigating a dynamic and evolving operating environment.

Following the separation, Abbott will remain one of the largest, most diversified and fastest-growing health care companies in the world. The Abbott portfolio will consist of even stronger mix of higher-growth, higher-margin businesses powered by technology and innovation. As a result, we expect Abbott sales growth to accelerate and margin profiles to expand. While the Abbott portfolio will evolve, maintaining balance across products, payers and geographies will remain a key strength and source of resilience for the company. We built this portfolio to hold market-leading positions in 3 of the most attractive areas of health care, med tech, Diagnostics and Established Pharmaceuticals.

The portfolio was also intentionally built to align with durable health care trends. including an aging population, increasing prevalence of chronic disease and the growing demand for earlier diagnosis and more personalized treatment. With market-leading positions, an industry-leading pipeline and a proven ability to consistently generate strong earnings growth and cash flow, Abbott is exceptionally well positioned to deliver sustainable growth and create long-term shareholder value in the years ahead. Cannot be more excited about this future. I have tremendous confidence in Abbott's future as an innovation-driven health care company, and I'm also confident in the opportunities that lie ahead for the new nutrition company. Most importantly, this creates 2 strong organizations that will both continue to fulfill our mission of helping people live better lives. We look forward to sharing updates on our progress as we move through the separation process.

I'll now review the third quarter results before I turn the call over to Phil. Sales grew 7% in the third quarter, and earnings per share grew 9%, representing an acceleration in growth on both top and bottom lines compared to our results in the first half of the year. Turning to Diagnostics where sales grew 6.5% driven by performance in our core laboratory and cancer diagnostic businesses Core Lab sales grew 5.5%, driven by strong performance in the U.S., Europe, Japan and Latin America. On our earnings call in July, I highlighted that test volume data sourced directly from thousands of instruments located across the U.S. and around the world, showed a pattern of strong and stable demand. We view this as a positive indicator of the underlying demand for health care more broadly.

During the third quarter, our testing data continued to support that view with testing demand remaining healthy and at durable levels. In cancer diagnostics, sales growth of 14% was driven by Cologuard and contributions to growth from our Precision Oncology and international businesses. In September, we launched our first blood-based colorectal cancer screening test as the only company to offer both stool-based and blood-based screening options. We are expanding the options available to health care providers and patients to help achieve the goal of getting more people screened.

Turning to Nutrition. Sales grew 5%, reflecting broad-based growth across all 4 categories: U.S. pediatric, international, pediatric, U.S. adult and international adult. As I mentioned earlier, the team has done an exceptional job executing a more balanced growth strategy, achieving a more sustainable mix of volume and price-driven growth. In Pediatric Nutrition, sales grew 9%, led by growth of 11% in the U.S. As I noted last quarter, the strong performance in the U.S. includes the benefit from WIC contract wins secured earlier this year, which helped Abbott regain its market leadership position in both the WIC and non-WIC segments.

In Adult Nutrition, sales increased 2%, driven by growth of 3.5% in the U.S. as retail consumption data continues to trend in a positive direction. We also continue to lead strong growth on a sequential basis with worldwide nutrition sales increasing more than $100 million compared to the second quarter. And finally, we continue to make good progress advancing our innovation pipeline. During the quarter, we launched a new version of our Similac infant formula made with whole milk. This new product is the first and only commercially sterile ready-to-feed liquid infant formula made with whole milk available in the United States.

Turning to EPD, where sales increased 8.5% in the quarter. Our broad portfolio of prescription and over-the-counter medicines tailored to address local health care needs continues to drive strong growth across emerging markets. Growth in the quarter was broad-based across geographies and therapeutic areas, and this included double-digit growth in several countries across Asia, Latin America and the Middle East, highlighting the strong and durable demand that has long been a hallmark of this business.

And I'll wrap up with Medical Devices, where sales grew 8%. Growth was well balanced across the portfolio, led by double-digit growth in Electrophysiology and Rhythm Management. In Electrophysiology, our third quarter results reflect the early beginning of our growth acceleration phase. Growth in the quarter was mid-teens or high teens when excluding LAA. In the U.S., growth was in the high teens and exceeded 20%, excluding LAA, this performance was driven by increasing adoption of our new Volt PFA catheter with momentum accelerating in September following the transition to a full U.S. market release in mid-August. International growth also accelerated as we continue to capture market share in Europe, driven by increasing uptake of our new PFA catheters and growth in other categories across our broad portfolio.

In September, we received FDA approval earlier than expected for our TactiFlex Duo catheter. The catheter enables physicians to seamlessly switch between using RF and PFA energy during a procedure. Given physicians' familiarity with the TactiFlex platform, we expect to execute a broad U.S. launch starting in the fourth quarter. In the third quarter, we also received CE Mark for our new Amulet 360 left atrial appendage device designed to help reduce the risk of stroke in patients with AFib. We look forward to bringing this new technology to the U.S.

In Rhythm Management, sales grew 10%, driven by increased adoption of AVEIR across both single- and dual-chamber segments of the pacemaker market. This expanding use of AVEIR is occurring in both the U.S. and international markets. And in Diabetes Care, continuous glucose moderating sales grew 8% in the quarter. In August, we received FDA approval for Libre Duo, the world's first dual glucose ketone biowearable sensor. This marks the first time that people with diabetes will be able to monitor ketones without the need for traditional blood or urine tests. We expect to launch this new sensor in the U.S. in December.

So I'm sorry, we delivered an acceleration in growth on both top and bottom lines. Innovation continues to be a key differentiator for Abbott, highlighted by multiple new product approvals and launches that further strengthen our ability to deliver sustainable growth in the years ahead. and we took an important strategic step towards shaping our future through the planned creation of a new market-leading nutrition company.

I'll now turn over the call to Phil.

Philip Boudreau

Thanks, Robert. Let me begin my remarks with an overview of some of the key aspects of our planning process for the separation. The new nutrition company will become a publicly traded company through a planned test free distribution to Abbott's shareholders. Upon completion of the separation, Abbott shareholders will own shares of both Abbott and the new nutrition company, enabling our shareholders to participate in the value creation opportunities of both businesses. The final share distribution ratio will be communicated prior to the separation, which we anticipate completing by the end of next year, subject to the required approvals.

We expect to incur separation-related costs as we progress through the separation process. These costs will be treated as specified items and excluded from adjusted earnings. As a result, do not expect the separation to have an impact on we plan to provide in January. As we prepare for the separation, we intend to establish capital structures that ensure both companies have a strong financial foundation. This includes ensuring adequate capital to support long-term growth objectives and capital allocation priorities while maintaining strong investment-grade credit ratings for both companies.

As part of that process, we are planning for the new company to raise debt with a portion of the proceeds to be distributed to Abbott, the amount of debt to be raised and the amount to be distributed to Abbott will be determined at a later date. Finally, we expect that both Abbott and the new nutrition company will pay a dividend that, when combined, will equal Abbott's dividend at the time of the separation. Following the separation, we expect Abbott's financial profile to reflect an acceleration in the sales growth and increased profitability. Excluding the current profile of the nutrition business from the current profile of the Abbott portfolio, we would expect sales growth to accelerate by 50 to 100 basis points, gross margin as a percent of sales to increase by more than 200 basis points and an operating margin as a percent of sales to increase by approximately 100 basis points.

Now turning to our third quarter results. Sales increased 7% on a comparable basis and adjusted earnings per share of $1.42 was in line with our guidance and the consents assessment. Foreign exchange had an unfavorable year-over-year impact of 0.4% on third quarter sales, which was a slight improvement compared to our expectations at the time of our earnings call in July. Regarding other aspects of the P&L, the adjusted gross margin profile was 57.2% of sales, representing an increase of 140 basis points compared to the prior year. The improvement in gross margin was broad-based, reflecting favorable business mix within the legacy Abbott portfolio and from the addition of Exact Sciences as well as the continued operational improvements and disciplined execution of our margin expansion initiatives.

Adjusted R&D was 6.9% of sales and adjusted SG&A was 26.9% of sales. Our operating margin of 23.4% expanded by 40 basis points compared to the prior year. And based on current rates, we expect exchange to have a negative impact of approximately 1% on fourth quarter sales. For the fourth quarter, we forecast adjusted earnings per share of $1.62 to $1.67.

With that, we'll now open the call for questions.

Operator

[Operator Instructions] And our first question will come from Robert Marcus from JPMorgan.

질의응답

Robert Marcus

Great. I'm sure others will ask on the business and the guide. But Robert, given the news this morning on Nutrition, I want to start with that to make sure we address it. Maybe you could run through the strategic rationale. Why now? Why spin versus sell? And any other important points you want to highlight for us?

Robert Ford

Sure, Robbie. I actually think that's the right call to start off. The right question to start off with to be quite honest, it's a pretty big announcement for us. And we've gone through a lot of work to be able -- to able to make this announcement today. I've seen a lot of notes be written about kind of the portfolio and all of those notes are from some of the parts and kind of growth rates and impact the growth rates and margin profiles. And I think Phil mentioned some of those. And those are all, I would say, good outputs of a decision like this. But I think it really starts with a very simple, as I laid it out, which is there's a huge opportunity that I think is building in this market in this segment. And we're seeing a shift towards a much more healthy nutrition behavior from consumers not just in this country but around the world. .

You're seeing a lot of traditional food companies try to reposition their portfolios, moving away from ultra process to try and look at their portfolios and ultimately try and build portfolios that try to mimic actually the portfolio that we actually have today. So I just think that strategically over the next decade, this is -- there's going to be a lot of segments in this nutrition business that we built that are going to be very differentiated and kind of high growth. And if you look at Nutrition's portfolio, it's positioned today, the capabilities that it has, it is destined to be a market leader and a market share of that entire segment that's going to have this accelerating growth here. But they are going to need to adapt, as I said in my comment, they are not going to need to evolve.

And ultimately, they are going to need to invest in kind of sales and marketing even maybe look at tuck-in M&A from their perspective to accelerate their growth rates and all of that. And I just -- we just came to the conclusion that this was too exciting of an opportunity, and we just believe that all the things that they would need to do, they'd probably be able to do it faster and more efficiently and effectively as an independent company. So it really just comes down to that. Yes, there's the -- I would say, the -- the ancillary effects of those decisions, Robbie, I think you've written good -- done a good analysis on that in terms of what that does for our growth rates and all that. But I think it really comes down to really the driver of the decision is this is going to be an exciting space. And as a result, we think that the nutrition business is going to be able to capitalize better on that by being an independent company.

From a financial asset perspective, I think this is going to be a very -- as we look at the spin, I think this is going to be a very, very unique asset. If you benchmark it versus its category peers, and not necessarily versus kind of the med tech peers that they're currently part of right now. It will have a very -- it will be a very differentiated asset whether you think about growth mix, the scientific capabilities have, its growth prospects. It's going to be, as I said, the only scaled truly global scale pure-play in this kind of healthy -- in this kind of healthy nutrition. So I think this is going to be a very, very distinct asset.

To your question on why now, listen, we've got a history of shaping the company. I think that's one of the hallmarks of Abbott, and that's, I think, why we're still relevant today after 138 years is that we will we will look at shaping the portfolio to align to where we see the market trending and where we see clinical needs and problems to be solved occurring. But as you do that, you also need to be thinking about sequencing. And I think sequencing is a key element as you think about shaping the portfolio. And they are very different elements of shaping. But for me, from an operational standpoint, I just think you need to be mindful of kind of organizational bandwidth and ability for the organization here to absorb the moves. So we have an order of events in mind of how we're thinking about things. I think we identified, for example, if you go back a couple of years, like we identified Precision Diagnostics as the next area that we wanted to be a part of. So we announced our acquisition of Exact Sciences last year. The integration is going great. Actually, I think we've done a lot of heavy lifting in these for 6 months have got a lot done. I'm sure we'll talk about that, too.

So I just think that now is the right time to start that process of creating a new company. It's coming from a position of strength, as I said in my comment, I think I read a story that just came out -- headline that just came out on Barron's who got it totally wrong. I'm just going to say, I mean, it's coming out of a position of strength. And we've got a very sustainable growth model. If you look at the volume growth that Nutrition had this quarter, and what we're projecting to have in the next few quarters, it is significantly higher than what its peer set is given the portfolio that we've built and the segments that we're in. So the business has returned to growth. The pipeline is very healthy. We're bringing innovations to the market. There's going to be a lot of interesting innovation over the next kind of 12 months here. We have strong brands, experienced and very capable team, as I said in my comment, I specifically dosed the term battle tested because that's kind of what it felt like over the last 4 or 5 years. And if I had to pick a team to go into battle with in this nutrition space, I'd pick that team. I think they've navigated very well everything that they've done and all the environment that they've operated in. So I think this is just a unique opportunity for us and for the Nutrition business.

And you had a question on spin versus sell. Yes, I mean, we just thought that this was after we went through the analysis, not to make a decision that it's probably going to operate better as an independent company, what the right mechanism there to be able to position it to be a leading company and ultimately, to drive shareholder value. And we just concluded that the spin-off here was absolutely the right approach. A sale of a business like this, as I said, we've been in this business since 1960. So if you think about the sale, the sale is going to come with an obvious tax implication there. And then a time line that is not necessarily within entirely within our control here. So I think these 2 factors might be a little bit prohibitive here for anybody that's got any interest. So we have no interest in selling the business. I have no intention to selling, not even looking at selling it and just think spin-off is the is the better value creation for shareholders year. We've done a couple -- obviously, we've done a couple of spin-offs in our history. Those have gone very well.

Obviously, different circumstances, different times, different management teams. And -- but I think one of the things that is clear to us in these processes is I think one of the big indicative indications here of a successful spin. I think a lot is attributed, I think, to a very highly group of Abbott people that become founders, so to say, of the new company, and they instill a lot of kind of the Abbott kind of culture and the Abbott way of doing things. into that business. And I think that helps set a strong foundation here. So like I said, I think this is a unique opportunity, growing demand for healthy nutrition. This will be a very differentiated asset here, and that's why I thought the spin was the better move here. So -- and obviously, we're going to be working over the next kind of 12 months here to be able to get ready for that.

And as we do with these, I think Robbie is -- we're obviously going to prepare to set up the nutrition company for success. But it's also an opportunity for us to relook also at existing Abbott and looking at our cost profiles and things like that, it's going to be a great opportunity for us to relook at everything from that perspective. So I think I'm excited about this. I think this is -- was a good process. I think we came to the right long-term strategic decision here. And now it's all about execution.

Operator

Our next question will come from Larry Biegelsen from Wells Fargo.

Larry Biegelsen

Robert, congrats on the Nutrition spin. Just confirm, please, that the net liability will remain with Abbott that seems logical from what we've seen from other spins. And secondly, can you please talk about the drivers of the revenue guidance reduction this year? It looks like it implies about 8% growth in Q4? And what are the implications for 2027?

Robert Ford

Sure. I figured this question would come up, Larry, I thought it will come up a little bit down in the list here. But -- well, I mean, like you said, as it pertains to the announcement that we just made, how to deal with litigation matters is -- it's a common topic. When it comes to business separations, we're not the first company that's had to deal with this, like you said. I don't think -- actually, it's pretty clear that we don't need to fully resolve the litigation matters. It's not a prerequisite for completing the separation. I'd say both Abbott and the new company are going to be well capitalized well capitalized to pursue their respective growth opportunities, we'll capitalize to execute the respective capital allocation priorities that they might have and also well capitalized to continue to defend the legal positions here.

So I'll provide more details of that as we progress in terms of exactly where the liability will sit. But for me, both companies are going to be super well capitalized to be able to deal with that. At the same time, I think we continue to focus on achieving what would -- what we want to be a logical and sensible kind of resolution. You saw we took a meaningful step back in August when we settled 2,000 claimants. But that settlement in no way reflects any change to the position that I've measured about these products, which is continue to stand behind their efficacy and safety. They remain essential components to neonatal care. They are a standard of care. I think if these products weren't available, I think you would see a little bit of a public health crisis there. And I think that view is supported by regulators in [indiscernible] societies, including the FDA, NIH, CDC and the American Academy of Pediatrics.

So I think the litigation environment now is shifting a little bit, I would say, a little bit to our favor. We prevailed a lot in federal MDL cases, and there's going to be important decisions in both federal and state courts that have helped increase our position. So we'll provide updates as we go through the process in terms of a little bit more specificity in detail. All I can say is not a prerequisite to resolve it before the separation and both companies will be well capitalized to be able to deal with this. So -- and then sorry, what was your -- what was your second question, Larry?

Larry Biegelsen

Yes. Sorry, the revenue guidance reduction, I think, to 6% this year implies about 8% for Q4. What was the driver or driver of the revenue reduction and implications for next year?

Robert Ford

Sure. Sure. Yes. Listen, our Q3 growth was in line with the expectation of 7%. We had the normal puts and takes, Larry, that you have when it comes to managing a lot of portfolio like us. We had 2 businesses that be expectations, one business that met expectations and then one business that missed expectations. So the reduction in to, for the full year, around 6%. Like you said, implies just north of 8%, which is at least accelerating versus where we were in Q3. It's really driven by 2 businesses here. And I would characterize these as they're not kind of permanent changes to the growth rate. It's just adjusting based on kind of what we're seeing right now, which is EP and diabetes.

So let me pack that a little bit for you. In EP, we're facing some short-term headwinds from dynamics related to the LAA market. It's become an increasingly headwind to our EP growth, not only due to the market challenges that I think a competitor has discussed pretty ample. But I'd say for us, so we saw that maybe with a quarter or 2 delayed versus where they were seeing it. And maybe that's just because of our size and market share position. But what was interesting is as soon as we got CE Mark for the new LAA device, there was almost like an immediate slowdown in orders here in the U.S., as I think accounts are waiting for the new products. So that's probably a little bit different for us is an -- so when I got that, I was like really -- and they were able to show me clearly kind of trends that we were seeing even with the slowdown and the impact of that CE mark.

So I expect that dynamic to be there in Q4. And I think that's going to be the last quarter where we're going to see this dynamic of accelerating kind of ablation business being offset a little bit by this headwind here. I think as we bring in 360 to the market, I think we'll start to kind of reignite that growth and capture share. at least that's my goal. But listen, despite the headwind, as I said in the prepared comments, I think the quarter we actually with a lot of great momentum continue to capture share in Europe. Europe growth was up 25%. And you have both combination both platforms there Volt and TactiFlex Duo. We're going to launch Volt in Japan sometime in Q4. That's going to turn Japan from a headwind to a tailwind for us. Japan kind of followed very much a U.S. type model where a very rapid adoption of PFA. So we're excited about coming to the market in the fourth quarter in Japan.

And I think both transitioned from limited market release to full market release in the U.S. in mid-August. So Q4, you'll have this kind of full quarter of the impact over there. And the product is doing very well and I think that I think people might have not have understood kind of the dynamics of what a limited market release is and then how you transition to [indiscernible] markets. And I explained why we do that. for all of our products. So TactiFlex Duo got approval in September. That came a little bit earlier than I expected. And as I said in the comments, this is one where the TactiFlex chassis like I will say, is widely used already. So we'll probably do a very short limited market release here very short and then go to full launch already in Q4. So I think that's going to provide a lot of momentum here. So we've got a lot of catalysts lined up for our business.

So I think the impact of that is about 5 points of growth versus where we were previously around 25%. I think we'll be around 20% in Q4. But I still believe even with the number we're going to be taking market share. So that's one of the drivers. The other driver is diabetes. I think in the July call, Larry, I talked about that the CGM market had not seen -- had not seen a significant new reimbursement expansion for quite some time. That led us to revise our diabetes growth outlook to high single. If I look into Q4 right now and probably for the next few quarters, and I now expect that growth rate to be in kind of that low to mid-single range. And that really is -- that change will reflect, I think, 2 things. One of them is a little bit of a harder challenge in penetrating the type 2 population in absence of the reimbursement expansion. So that's probably one kind of key driver. And I guess that's going to be when we see the reimbursement expansion occurred at CMS. And like I said, I think we'll see a very strong kind of reimbursement growth. So that's one element there, Larry.

I think the other element that we're seeing is a little bit more pricing pressure in the international markets. And as you might know, we have significant market share in the international markets. If you look at all the major countries, we'll range between 50% to 70% market share. And we've all expected there to be some pricing pressure, especially with the growth of the category and the excitement. And we've been -- internationally, I think you see a lot more competition. And we've been very good. I think the team has done an excellent job through marketing, through clinical, through all the superior of the product over the last couple of years to be able to defend that. So I expect it to be a little bit more price pressure internationally a little bit earlier. So I think the team did a really good job there. But I think our pricing actions here that we're going to have to take internationally are going to are going to kind of mute a little bit of the volume growth that we're seeing. And this -- I think it will be a strategic mistake for us to lose market share based on price in these international markets.

And we're not having to match the pricing, Larry, but I think we're having to adjust a little bit here as we go through this. And I think that's what I'm forecasting here over the next kind of few quarters is we'll make some pricing adjustments as we do those, we're going to secure longer-term contracts and then also have language there regarding kind of expansions of patient populations also. So I think you have this dynamic here for a couple of quarters in our diabetes business. so that we can make sure that we can defend our market share position. And then I think -- I think what you'll see then is kind of similar to the kind of decisions we made in other parts of the portfolio where you have a little bit of an impact for a couple of quarters and then you kind of reignite. I don't think this is at all any issue with the market. I've been pretty adamant about the ability still for there to be lots of market penetration.

But I mean we're not going to have our heads in the sand here and just think that you've got this great market and not expect there to be some price competition. The good thing for us, though, I would say is because of the scale that we built and because we've been planning for this and being ready for this, we're going to be able to offset kind of the margin impact of that through our COGS programs and the things that we've been doing in our manufacturing setup. So I think that's really the driver. But I would say if you look at -- we've got plenty of growth opportunities also, Larry. So when I kind of set that target at kind of low to mid. If I look at what we've got ahead of us, Libre Duo is going to launch. We really haven't launched that product yet. And I think that's going to be a nice growth driver for us next year.

We're going to have a benefit here in the U.S. from a pretty significant payer formulary coverage that flipped in our favor, and that's going to go into effect January 1. So there's a lot of growth opportunities that we've got in our diabetes business. Would I be surprised that we would do much better than that next year. It would not surprise me at all that we would do better. But at this point, I'd say we got to make sure we get the pricing aspect right. And then we'll -- as we go through the year, we'll be factoring in some of these growth drivers and the implications that they have. So if you think about 2027, then I think as you're looking at, okay, how does that translate into 2027. I expect to see acceleration in our total company growth rate. And there's a lot of reasons why we would expect that. But I would say we're probably going to take a little bit more of a conservative approach here in terms of how we've guided historically, at least on the top line.

We've maintained, I'd say, a pretty impressive track record for delivering on our EPS targets. I think if you go back for the last 6 years, we've met or beat our EPS targets every single quarter. And if you look at the annual growth rate of those -- of what we've been doing for EPS, it's been around 9% EPS growth. So I think we've been really good and strong over there. As it relates to our top line I think we've been very good, but I'd say the track record here in the last couple of quarters or especially during this year has been a little bit more inconsistent, let's call it like that, and we've fallen short from some of the expectations. So I think for 2027, I think we'll set our guidance that's going to create opportunity for us to move up from there in January. I'm not going to give an official guidance here before our January's call. But high level, I'd say forecasting sales to be as we come out of the gate pretty similar to this year. And I think that's just probably feels like the right place to start.

And Larry, I say that, while I acknowledge that we have a lot of new product launches this year, there's a lot of carryover from the products we launched this year into next year. There's a lot of new products we're launching in 2027. I get that there's probably some comp also, especially in the first half. So I get all that. And all of that would obviously say, hey, you probably can accelerate your 2027 growth versus in 2026. I strongly feel that, that's going to be the case. But I said to start off, I think we'll take a little bit more of a different approach than what we've done in the past, and then we'll be able to go up and move up from there. That being said, we're still going to have great opportunity for gross margin and gross margin expansion. We're still going to have earnings growth. We're still going to be investing in our in our near and long-term product pipelines. We're still going to be able to generate real strong cash flows. We'll grow our dividend. All the stuff that you would expect from Abbott, we're going to be doing all of that. But I think that's probably a prudent way to start the year and that's going to give us the opportunity to kind of move up through the -- as the year progresses.

Operator

Our next question will come from Patrick Wood from UBS.

Patrick Andrew Wood

I'd love to start on the pipeline and really just dig into that because obviously, you've got conduction system pacing midterm and the 360, probably $200 billion of biologic drugs going through LOE. There's obviously a lot of midterm that's going on. And so I guess my question is in 2 parts. A, how do you feel about the forward pipeline today compared to the forward pipeline in the past? How would you rate it? And b, as you're thinking about it, not asking you to pick your favorite children, but what do you feel like either gets missed by the market or less attention, but something that's really on your radar and very personally a big sort of focus area for you.

Robert Ford

Sure. I mean I love all of our innovations because I don't think you're going to get me to go there. But I would say, listen, I think the market recognizes the pipeline that Abbott's built. I don't think that there is a misunderstanding of what we're assembling over here. So we can talk about those. But I don't think there's like some misunderstanding. I think it's clearly visible to investors that we've got multiple shots we're developing across all of our businesses Yes. And some of them will do better than others, but I think all of them will have great contributions to our growth rate. And yes, what we need is 1 or 2 to kind of completely blow it out, and it kind of changes the entire trajectory. But we're building a pipeline of products organically here that anticipating what our customers need, and we're making those investments.

If you look at the R&D spend, for at pre-COVID, I mean we were averaging around $1.7 billion, $1.8 billion. We're crossing $3 billion this year, and we'll be increasing that into next year, which was kind of to my comment in 2027. We're going to continue to make our investments. We're going to continue to expand margins, and we can do all that. because of how the portfolio is positioned into these very high growth, high-margin and quite frankly, a lot of clinical problems to solve. So I think you mentioned a couple of them there. I've talked about some of them. I'm excited about the -- you mentioned at the get-go the AVEIR CSP that's going into trial right now, the conduction system piecing lead this product. I'm excited about that because our goal is to completely change how pacemakers have been used in the past. And I think our leadless technology shows that it is possible, and we're looking about really building a kind of sustained growth rate here.

Many people didn't think that CRM was a growth business. We're showing that with good innovation, good insights, good relationships with KOLs, we can drive that. I'm excited about the mitral replacement valve. I've spent some time close to that program, probably a little bit more closer than others and had opportunity to interact with the KOLs. And I know because I've seen how these things play out. I can read people in terms of how they talk about innovations. And you can tell sometimes when innovation is good and compete well. And you can tell when a KOL tells you that this is really going to be a game changer, and it's going to change kind of the standard. And I think our Cephea program is going to do that. We've got a balloon expandable TAVR valve going in. We've got IVL programs on the med tech. We've gotten neuromodulation kind of instance that we're making also.

We're making investments in our Libre platform not just on a new diabetes sensor, but also looking at how to use the platform that we've built the manufacturing and the technology platform to expand into other analytes and we're going to go into a trial with a lactate sensor. But I can tell you there's at least 5 or 6 that the team is really excited that we're funding that we're funding on, that we're working on. Well, all of them hit? Probably not. But if we're 3 hit, it will be incredible, I think, to be able to kind of leverage that. So I think you mentioned the biosimilars in our EPD business. I mean, yes, there's a significant amount of LOE that's happening in the biologics space. And a lot of these products aren't available in these emerging markets by decisions from the originator. So this is going to be a huge opportunity for us to leverage the regulatory, the government the physician, the distribution relations that we have to bring these products on. And you've got this business that's been growing at least for the last 5 years, between 7.5% and 8% pretty consistently every single quarter.

I think that, that is going to be very exciting also. So -- and then on top of that, we're going to get into a bunch of new tests new personalized diagnostic test with our cancer diagnostic business we're going to be reporting data on our MRD test at ESMO. I'm extremely excited about that test. And I think this is going to provide us an opportunity also to start to be a player or at least to compete effectively in that segment of the market. So I'm sure I'm missing a bunch out already, too, but I'd say there's a deliberate effort on behalf of the entire management team here to make sure that as we as we find sometimes challenges, and we have to look at our operational expenses that R&D is really ever an area that we're going to touch because we feel that our productivity in that, even with a 7% profile, we're getting a lot of productivity out of the pipeline.

So I think that, that is ultimately the lifeline that is going to be the growth driver for us. I'm sure that somebody in my team has got a map. I'm sure that my team has a map that lists out all the products between '28, '29, '30, '31, and those are all projects that we're constantly looking at looking at ways to accelerate them, looking at ways to make them better. So we feel very good about our pipeline. At the same time, we don't suffer from the syndrome of not invented here. We never have. Do I prefer to have more of my organic -- innovation being organic, I do. But we've got plenty of capacity also to be able to kind of add to the portfolio. And if we see opportunities to do that, we'll do that. I've talked about probably going forward, at least for the foreseeable future here in the short term, there will probably be more tuck-in deals. But we do all that. We can have organic innovation, and we can also look externally.

And I think external partners look at Abbott as like, okay, this is a company that can actually make these innovations really impactful and global in the market. So I think we have a good position there, too. So pipeline is super healthy. And if my R&D team is listening to this, they'll probably say, yes, we could probably use more. They probably have a bunch of projects under the line, and that's good, too. But I think we're investing in all the right areas to be able to sustain our growth.

Operator

Our next question will come from Matt Taylor from Jefferies.

Matthew Taylor

I was hoping we could spend a minute or 2 on diagnostics and focused on cancer diagnostics and the dense there. Looks like you did a little bit better this quarter, but I know you're hoping for a step up into the mid-teens. Could you just touch on the dynamics with Cologuard, the rest of the business? And maybe give us some thoughts on Freenome?

Robert Ford

Sure. Yes. So we were -- we grew 14%. I think consensus was just north of that, like 15%, 15.5%. So it came a little bit short. Was I expecting to do higher than both those numbers? You bet I was. I'd say the biggest driver of that delta versus expectation there was the cybersecurity event that we had in July. That caused us to lose a little bit of momentum. I think you see a lot of companies, including a few of our health care peers have had to deal with that. Some of them with, I'd say, worse outcomes than what we went through. I think the team did a really good job. I mean if you think about an integration process, dealing with the cyber attack is not on the menu. And I think that the guys did an incredible job to be able to mitigate that. When they did bring me the forecast and they talked about, well, the cyber had an impact. I -- as you would expect, I had to double click on that.

And we saw a couple of accounts, Matt, because of the connectivity in the system, the way we're connected to the system. You saw a couple of systems shut the connectivity down so we could bring them evidence that, hey, everything was up to speed. So then when you do that, then you're reverting back to faxes and e-mails and stuff like that, that -- so there were notable kind of drops. But then as soon as the systems return right back on, you saw that they pop right back up. So that -- those blips, which lasts at about 7 to 10 days, that causes about 1 point of growth. So yes, I expect it to do better than what we deliver. But still -- and I know the team did also, but I think they did a really good job managing that. But I think that the growth is great. I think we're seeing -- I'm really pleased with the integration and kind of how things are going.

Cologuard grew mid-teens and continues to accelerate. We're seeing growth in new users, which is really important to be able to show that growth in new users. Obviously, the rescreen business is doing very well. The international growth rate is happening. The care gap program is growing also. It's definitely a growth segment for us. It's just probably a little bit harder to forecast. And I'm learning a little bit more about the difficulties in that forecasting right now. We obviously build a plan as to when we're going to send these orders out. Obviously, the insurance companies and the health systems will determine when they want that out and sometimes they're managing their expenses, but it's very clear to me that the need for these brands in place so that it fits into their star ratings and into all of their Medicare CMS rebate is super important, and they value this hugely. It's really a question of timing. But we had good growth in our care gap programs, too.

So I'd say from a top line perspective, I feel very good about where this business is going, and it's doing everything that we expected it to do. I'm excited about the pipeline also. You mentioned the CRC blood test. I mean, we just -- it literally was Matt, I think it was like September 30, they started kind of sending out the e-mails and starting to promote and all of that. So really didn't have much impact in Q3. Do I think it's going to have a contribution to our growth rate, Yes, it will. Obviously, the ASP to that product is higher than the ASP that we have for Cologuard. So that's going to be a growth driver for us also. It's always got a different margin profile as we're working with a partner, but we've factored all that in, not only in our deal mobile as we're going forward.

I think it's going to play an important role. Do I think it's the preferred past? No, we don't. And nor does the medical societies, the Cancer Society and a lot of the standard of care recommendations to go with stool first for a lot of reasons, but predominantly because your -- you've got a better performance in earlier detection. And ultimately, that's what screening is all about. You're trying to detect early. So -- but it does play a role in the portfolio. And I think that gives us the opportunity, as I said in my on my comments, we're really positioning ourselves here as the only company that has the broadest portfolio with both blood-based and school-based testing. And I think that puts us in an advantage as we talk to all the different value players, all the different stakeholders in the value chain, I think that puts us in the position of, okay, we've got all the different technologies here to be able to do that.

So I feel good about the test. I think it's going to be an important test to have in the back, especially for those that aren't doing anything. So maybe this could be used as a way to get them to start to think about it since it's pretty convenient. But I'm -- we just got to be careful about how these things are promoted and how the accuracy of the information that's being portrayed to the consumer is complete and transparent and some of the deficiencies that the blood still has. I mean I think it's going to get better. It's got to get better. It will get better. It's just right now, the detection on the precancerous lesion side is not as good as what Cologuard is. So -- and then as I said also, I think the MRD test that we're going to be presenting at ESMO, I think that's going to be a great opportunity. So pipeline is doing good. The international business, the opportunity to bring this technology internationally, and we've been doing a lot of great work over there.

We've already selected the markets that we're going to go after. They wouldn't be what you would typically expect those markets to be, but the markets that we feel will have the biggest impact, but I'll tell you what I'm really impressed is kind of the progress we're making from a margin perspective. We're able to do all best, grow the business, invest in the pipeline and really kind of also change the trajectory of the profitability there. So if you look at this business and its operating margin profile before we acquired it, it just turned slightly positive. We're exiting Q3 with an operating margin profile in the high teens already with this business. So I think that's I think that's very positive also that we can drive the top line and also drive the bottom line. As I've always said, for us does matter. Yes, we do care about the top line, but EPS also matters. And I think the teams have been able to do both of those. So overall, I think the business is going well. And we've got a lot of growth opportunities ahead of us, whether it's with existing products, expanding into different areas, segments, countries or bringing new products to the market also.

Operator

Our next question will come from Vijay Kumar from Evercore ISI.

Vijay Kumar

I have 2 questions. Maybe I'll ask both of them upfront. One follow-up on this exact did Cologuard 2.0, the next-gen Cologuard did the reimbursement get cut, Robert? And what's the ASP for the splug test rate? It feels like Exact should accelerate? And then my second question was fiscal '27. Thanks for the color on top line. But are you still -- should we still be aiming for double-digit EPS growth?

Robert Ford

Yes. Sure. Let's talk about your first question regarding Cologuard Plus and getting a reimbursement -- listen, Cologuard Plus is a new test. So the process for setting CMS reimbursement was a little bit different versus tests that have been on the market for a while. We've been in active discussions with CMS. Conversations have been very productive. I'll just say the following. I find it very hard to imagine that when the process is done, that the reimbursement rate for Cologuard Plus would go down. And I'm just going to that. It is an interesting process, very different, I would say, from kind of NCDs and some of the med tech kind of process. So it is a new -- it's a little bit of a new process for us.

But like I said, I'd be very surprised if that were to happen. I think you asked about the price of our blood test. Yes, I'm not going to divulge that because for obvious competitive reasons. There is a -- there's somewhat of a kind of price that's been set by the market right now. We have an opportunity here to think about broad adoption of the technology. I find it difficult to believe that you'll get kind of the kind of uptake in any kind of blood type test at these rates. Yes, they'll show good growth rates, and you'll penetrate a very small part of the market and you'd be able to show. But I think that for this market to really expand. And now I'm going beyond just kind of simple screen. I'm just talking about it just more holistically. If we're going to want to see this type of testing become kind of standard of care and there's going to be a very large amount of -- at least in this country, forecast is that 40% of adults are going to have some level of cancer.

If you're going to have an impact and using diagnostics as a way to kind of help eradicate and bring down these rates and increase like there needs to be a much broader adoption. And you're not going to be able to get that broader adoption with the kind of pricing strategies that are being applied today. So we're being mindful of that, and we're thinking about that. We're in discussions with payers and we're really looking at how do we compose a full portfolio of cancer diagnostic solutions for those that are paying for it. So that's what I'll say about pricing right now. And then what was your other question?

Vijay Kumar

Double-digit EPS for fiscal '27. Is that still a number?

Robert Ford

Yes, I get that you guys are going to start to try and triangulate as much as you can there. Like I said, I'm not going to give kind of total guidance from -- on this call, we're probably going to do that in January. All I'll say is, I mean, I gave you a little bit in terms of how we're thinking about our top line. But like I said, we're going to have EPS growth. We're going to have gross margin expansion. We're going to have all the things you would expect and probably leave the actual specific guidance range for EPS and all other elements, cash flow all of that, we'll leave that to January.

Operator

Next question will come from Travis Steed from BoA Securities.

Travis Steed

At TCT in a couple of weeks, we've got Amulet 360 pivotal data and coronary IVL pivotal data. Just curious anything you could say on that? And then how quickly those products can launch. It seems like doctors are already waiting on Amulet 360 today. comment on how much share you can take or kind of view on when the [indiscernible] closure market stabilizes?

Robert Ford

Yes. So you got 2 important readouts for us at TCT this year. I think we'll have more. But yes, I know those will gain a lot of attention. I mean I'm not going to preface what the data is going to say, we'll wait for the investigators to kind of lay out that information but I think these are -- I think we showed a 45-day data the Boston meeting back in January, Travis, for our LAA device, and I think that's a kind of good benchmark to have there. Regarding the market, yes, I mean, I we started to feel some of these challenges. I'd say maybe 1 or 2 quarters after the market leader. I think that the way to counter that is there's definitely an opportunity here still to educate this opportunity to make continued clinical investments to be able to show the technology.

Obviously, the market leader has been doing that. But so have we. I mean we're going to have a readout of our trial not next year, but probably the year after that on our trial versus NOACs. And I just think you got to keep on investing as clearly a benefit here for the patients and the health systems, they want this. We are investing in a lot of stroke prevention technologies. This is one. It's obviously the one that gets a lot of attention. but we probably have another 2 or 3 products that are in early stage in our venture arms that we're also kind of working on because I think this is just going to be a need, a continued need. So I think the market is going to continue to grow, and that's why we're going to continue to invest in it in terms of our ability to forecast how much share. I'll let you guys -- you'll probably do your checks with physicians and try and triangulate that. I'll let you guys kind of decide what that's going to be. But we think we've got a very competitive product that not only has added some ease of use to its implant, but it also maintains what we believe is a superior seal technology there.

So yes, we feel good about it. And I think on -- I think you had -- on the IVL, yes, I think this is an interesting category. It's a $1 billion-plus market that's growing. We didn't have to spend over $10 billion to get an asset like this. We did it through our acquisition of CSI. Team took over the project, did some modifications really good work by the team and our partner, and we filed for at least for the coronary side, we filed for approval I don't know exactly when, but I know we're expecting it sometime in the first half and maybe we might surprise on the earlier side there. But I think we feel good about it, adding that to the portfolio. I think the vascular team is really looking forward to this. I think you've seen that we've been able to accelerate our growth from kind of a negative flat business to like now consistently delivering mid-single digits. And I think this just adds to the ability to kind of accelerate growth in our vascular business, too. So -- and I think we'll start our peripheral IVL trial at the end of the year. So those 2 products will add to the growth rate in our vascular business.

Michael Comilla

Crystal, we'll take one more question, please.

Operator

Our last question will come from Joanne Wuensch from Citi.

Joanne Wuensch

Congrats on the Nutrition spin. Briefly, can you comment on potential reimbursement from CMS for non-intensive type 2 for CGM use. And a quick follow-up. Does anything in your pending spin of nutrition impact any of your other strategic plans such as future M&A?

Robert Ford

Sure. I know this is the -- I don't know what kind of -- what I would characterize, but I know it's a big question, which is when do we expect the type 2 non-insulin user reimbursement, CMS reimburse kick in. I'm just going to be consistent here, Joanne, I'm not going to try and forecast that. What I can say is that the clinical data is significant. It is very real. I know that there are many in those that are making those decisions that believe in the value of data of predictive data of using continuous data to be able to kind of shape behavior I've said this multiple times, CGM the behavior modification tool. They're not doing anything your body. They're not changing any of the biology, anything in there. They're just giving you information. And there's a lot of people that believe that, that information is valuable to change behavior, especially with type 2 non-insulin patients and the clinical data that has been presented has shown that the same way the clinical data with basal patients has shown that, too.

So there is definitely support for it. There's a clinical support. And -- but trying to forecast exactly when that's going to happen. I am not going to do that. I am not going to say that it is embedded in the forecast for next year or -- right now, what I can say is I'm not really factoring it in. But I know that when it does kick in, like we've seen this in the past, acceleration happens. And when that happens, I think that what we're doing is preparing ourselves to be in the best possible position. It is a different channel, right? You're not in the diabetes endo clinics or in primary care. This is a different. It's a different field of play. And we've been investing in that field for quite some time now. So I think we'll be in a good position to be able to capitalize on that, but trying to forecast it. I'm not going to try and do that, Joanne. But I can say that the momentum to be able to do it, the clinical support, all of that is all in place. It's really a question as to when that's going to happen. Sure you maybe have read the comments, the open comment period, there's plenty of support. It's just really an opportunity here as to when that's going to happen. And then what was your second question again?

Joanne Wuensch

It had to do with the nutrition span if it impacts any of the changes in M&A, et cetera. it's an M&A question.

Robert Ford

That's fine. Listen, the answer to that is a big note. It has no kind of impact. If anything, I'd say once we go through that, I think it even strengthens it even more. Our balance sheet is in very great shape. We've got a lot of flexibility. You know our philosophy here of taking a more balanced approach. I'm not going to give you percentages of how which goes there, how much but we take a balanced approach. We'll grow the dividend next year, right? We've got probably the last tower of debt pay down related to the St. Jude, AVEIR acquisitions will occur this year. And then we have very few kind of debt payments in a couple of years following that. So I think we'll be in position there. We'll have opportunity for buyback. We've got plenty of raw there.

On the M&A side, yes, I mean, I said this last time, we're obviously focusing on the exact integration. I think the team has done an amazing job at the speed at which they've done this is really good. Our net debt to EBITDA is going to be around 2x. So we still have plenty of capacity. But I would say as we look around, it's probably more in the tuck-in range than it is on kind of more transformative, I would say, just because I don't -- not sure I see anything that's exciting out there right now, at least kind of in kind of in that kind of start-up kind of mode. I think there's some really early-stage stuff that we're very excited about. And that we're investing in from a venture perspective, but we've got plenty of opportunity. And if there's going to be. And if there -- if the opportunity aligns with the right moment and sequencing, like I said, we've got capacity to do that.

But I'd say they're probably more tuck-in than anything else. So no, that doesn't affect our ability to continue to grow the dividend, invest in our organic opportunities and do M&A, too. So I think we're in good shape. So I know I've gone over here, and I expect it to go over, so I appreciate everybody kind of hanging in there. I'd say, listen, we had a very good quarter, delivered an acceleration on the top and the bottom line. I think one of the questions that was asked there, as I've said, innovation is the key differentiator at Abbott. And we don't want to be overly reliant on 1 or 2 products. We've got opportunities across all of our businesses, and we've got multiple new product approvals that are going to carry into next year. We're going to have product launches that are going to into that are going to occur in next year and will ramp up in next year.

So I think that, that is probably our biggest driver of sustainability here is our pipeline is very healthy. Teams are doing a great job at navigating what I would say is a pretty volatile environment right now around Globe and teams have done an incredible job there, and I think they're going to continue to do that job as they continue to be motivated and inspired by the work that we're doing. And we took this pretty big important step here towards shaping the future. And I think that's how that's how one needs to look this is we're not making quarterly decisions here, but looking ahead the next 5, 10 years, what's the right portfolio to assemble. And I think opportunity that's going to be ahead of this nutrition company is going to be pretty significant, and I'm excited for them, but I'm also excited for the Abbott portfolio. So thanks for being on the call.

Michael Comilla

Thank you all for your questions. This now concludes the Abbott's conference call. A webcast replay of this call will be available after 11:00 a.m. Central Time today on our website, abbott.com. Thank you all for joining us.

Operator

Thank you. This concludes today's conference call. Thank you for your participation. You may now disconnect. Everyone, have a wonderful day.